乳腺癌经济毒性研究进展

Abstract
Figure/Table
References (30)
Related Citation (15)

Download: PDF (663 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract The term “Financial toxicity” is widely used to describe the distress or hardship suffering from the financial burden of cancer treatment. High medical costs and reduced income after diagnosis of the disease have contributed to financial toxicity. A large proportion of breast cancer patients have experienced financial toxicity in Western counties, however, this has been rarely reported in China. Financial toxicity has many effects on patients and their families, including lifestyle changes, poor treatment compliance and delayed treatment, which in turn affects quality of life and mental health, and leads to poor prognosis. A variety of ways need to be implemented in order to reduce financial toxicity, including government policy support and discussion about cost-effective between doctors and patients. Further research is needed to provide Chinese patients evidence of most appropriate intervention targets, content and timing.

Key words： Breast cancer Financial toxicity Influencing factors Intervention measure

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	JING Jingfeng1 GAO Jinnan2 LI Dong2 YANG Haibo2

Cite this article:

JING Jingfeng1 GAO Jinnan2 LI Dong2 YANG Haibo2. Progress of research on financial toxicity of breast cancer[J]. 中国医药导报, 2019, 16(32): 30-33.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2019/V16/I32/30

[1] Huang HY，Shi JF，Guo LW，et al. Expenditure and financial burden for common cancers in China：a hospital-based multicentre cross-sectional study [J]. Lancet，2016， 388：S10.
[2] Zafar SY. Financial Toxicity of Cancer Care：It′s Time to Intervene [J]. J Natl Cancer Inst，2016，108（5）：370-373.
[3] Zafar SY，Abernethy AP. Financial toxicity，Part Ⅰ：a new name for a growing problem [J]. Oncology，2013，27（2）：80-83.
[4] Gordon LG，Merollini KMD，Lowe A. Systematic Review of Financial Toxicity Among Cancer Survivors：We Can't Pay the Co-Pay [J]. Patient，2017，10（3）：295-309.
[5] Davidoff AJ，Erten M，Shaffer T，et al. Out-of-pocket health care expenditure burden for Medicare beneficiaries with cancer [J]. Cancer，2013，119（6）：1257-1265.
[6] Chan RJ，Gordon LG. Financial toxicity among patients with cancer-where to from here? [J]. Cancer Nurs，2017，40（4）：257-258.
[7] Xu TT，Wu J. Financial toxicity of cancer in China [J]. J Cancer Policy，2018，15（7）：96-99.
[8] Saito N，Takahashi M，Sairenchi T，et al. The Impact of Breast Cancer on Employment among Japanese Women [J]. J Occup Health，2014，56（1）：49-55.
[9] Lauzier S，Maunsell E，Drolet M，et al. Wage losses in the year after breast cancer：extent and determinants among Canadian women [J]. J Natl Cancer Inst，2008，100（5）：321-332.
[10] Su TT，Azzani M，Tan FL，et al. Breast cancer survivors：return to work and wage loss in selected hospitals in Malaysia [J]. Support Care Cancer，2018，26（5）：1617-1624.
[11] Jagsi R，Pottow JA，Griffith KA，et al. Long-term financial burden of breast cancer：Experiences of a diverse cohort of survivors identified through population-based registries [J]. J Clin Oncol，2014，32（12）：1269-1276.
[12] Irwin B，Kimmick G，Altomare I，et al. Patient experience and attitudes toward addressing the cost of breast cancer care [J]. Oncologist，2014，19（11）：1135-1140.
[13] Rosenzweig M，West M，Matthews J，et al. Financial Toxicity Among Women With Metastatic Breast Cancer [J]. Oncology Nursing Forum，2019，46（1）：83-91.
[14] Azzani M，Roslani AC，Su TT. The perceived cancer-related financial hardship among patients and their families：a systematic review [J]. Support Care Cancer，2015， 23（3）：889-898.
[15] Giordano SH，Niu J，Chavez-MacGregor M，et al. Estimating regimen-specific costs of chemotherapy for breast cancer：Observational cohort study [J]. Cancer，2016，122（22）：3447-3455.
[16] Dean LT，Moss SL，Ransome Y，et al. It still affects our economic situation：long-term economic burden of breast cancer and lymphedema [J]. Supportive Care Cancer，2019，27（5）：1697-1708.
[17] Kong YC，Bhoo-Pathy N，Wong LP，et al. Impact of cancer on employment：A qualitative study exploring employment changes and financial coping strategies following breast cancer [J]. Adv Mod Oncol Res，2017，3（6）：296.
[18] Zafar SY，Peppercorn JM，Schrag D，et al. The financial toxicity of cancer treatment：a pilot study assessing out-of-pocket expenses and the insured cancer patient′s experience [J]. Oncologist，2013，18（4）：381-390.
[19] Neugut AI，Subar M，Wilde ET，et al. Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer [J]. J Clin Oncol，2011，29（18）：2534-2542.
[20] Sharp L，Timmons A. Pre-diagnosis employment status and financial circumstances predict cancer-related financial stress and strain among breast and prostate cancer survivors [J]. Support Care Cancer，2016，24（2）：699-709.
[21] Meeker CR，Geynisman DM，Egleston BL，et al. Relationships among financial distress，emotional distress，and overall distress in insured patients with cancer [J]. J Oncol Prac，2016，12（7）：755-764.
[22] Lentz R，Benson AB，Kircher S. Financial toxicity in cancer care：Prevalence，causes，consequences，and reduction strategies [J]. J Surg Oncol，2019，120（1）：85-92.
[23] Xia J，Tang Z，Deng Q，et al. Predictors of the quality of life in Chinese breast cancer survivors [J]. Breast Cancer Res Treat，2018，167（2）：537-545.
[24] Ramsey SD，Bansal A. Financial insolvency as a risk factor for early mortality among patients with cancer [J]. J Clin Oncol，2016，34（9）：980-986.
[25] Hershman DL，Shao T，Kushi LH，et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer [J]. Breast Cancer Res Treat，2011，126（2）：529-537.
[26] Schnipper LE，Davidson NE，Wollins DS，et al. American Society of Clinical Oncology Statement：A Conceptual Framework to Assess the Value of Cancer Treatment Options [J]. J Clin Oncol，2015，33（23）：2563-2577.
[27] Cherny NI，Sullivan R，Dafni U，et al. A standardised，generic，validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies：The European Society for Medical Oncology Magnitude of Clinical Benefit Scale （ESMO-MCBS） [J]. Ann Oncol，2017，28（11）：2901-2905.
[28] Meropol NJ，Schrag D，Smith TJ，et al. American Society of Clinical Oncology guidance statement：The cost of cancer care [J]. J Clin Oncol，2009，27（23）：3868-3874.
[29] Tucker-Seeley RD，Yabroff KR. Minimizing the “Financial Toxicity” Associated With Cancer Care：Advancing the Research Agenda [J]. J Natl Cancer Inst，2016，108（5）：410.
[30] Kaser E，Shaw J，Marven M，et al. Communication about high-cost drugs in oncology the patient view [J]. Ann Oncol，2010，21（9）：1910-1914.